Respiratory syncytial virus vaccines

Clinical Microbiology Reviews

Volumn 11, Issue 3, 1998, Pages 430-439

  Dudas, Robert A ^a   Karron, Ruth A ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; LIVE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS VECTOR;

ADOLESCENT; ADULT; AGED; CHILD; CLINICAL TRIAL; GENETIC ENGINEERING; HUMAN; IMMUNE DEFICIENCY; INFANT; LOWER RESPIRATORY TRACT INFECTION; NEWBORN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS CLASSIFICATION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS MORPHOLOGY;

EID: 0031848862     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.11.3.430     Document Type: Review

References (126)

1. Akerlind, B., and E. Norrby. 1986. Occurrence of respiratory syncytial virus subtypes A and B strains in Sweden. J. Med. Virol. 19:241-247.
2. Andersen, L. J., R. M. Hendry, L. T. Pierik, C. Tsou, and K. McIntosh. 1991. Multicenter study of strains of respiratory syncytial virus. J. Infect. Dis. 163:687-692.
3. Bangham, C. R. M., M. J. Cannon, D. T. Karzon, and B. A. Askonas. 1985. Cytotoxic T-cell response to respiratory syncytial virus in mice. J. Virol. 56:55-59.
4. Bangham, C. R. M., P. J. M. Openshaw, L. A. Ball, A. M. Q. King, G. W. Wertz, and B. A. Askonas. 1986. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J. Immunol. 137:3973-3977.
5. Beem, M. 1967. Repeated infections with respiratory syncytial virus. J. Immunol. 98:1115-1122.
6. Belshe, R. B. 1993. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J. Infect. Dis. 168:1024-1029.
7. Berkovich, S. 1964. Acute respiratory illness in the premature nursery associated with respiratory syncytial virus infections. Pediatrics 34:753-760.
8. Brideau, R. J., and M. W. Wathen. 1991. A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice. Vaccine 9:863-864.
9. Bukreyev, A., E. Camargo, and P. L. Collins. 1996. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J. Virol. 70:6634-6641.
10. Bukreyev, A., S. S. Whitehead, B. R. Murphy, and P. L. Collins. 1997. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:8973-8982.
11. Cane, P. A., D. A. Matthews, and C. R. Pringle. 1992. Analysis of relatedness of subgroup A respiratory syncytial viruses isolated worldwide. Virus Res. 25:15-22.
12. Cane, P. A., and C. R. Pringle. 1995. Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein. J. Virol. 69:2918-2925.
13. Cannon, M. J., P. J. M. Openshaw, and B. A. Askonas. 1988. T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 168:1163-1168.
14. Cannon, M. J., E. J. Stott, G. Taylor, and B. A. Aksonas. 1987. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology 62:133-138.
15. Chanock, R. M., H. W. Kim, A. J. Vargosko, et al. 1961. Respiratory syncytial virus. I. Virus recovery and other observations during 1960 out-related of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 176:647-653.
16. Chanock, R. M., and B. M. Murphy. 1991. Past efforts to develop safe and effective RSV vaccines, p. 35-42. In B. Meignier, B. Murphy, and P. Ogra (ed.), Animal models of respiratory syncytial virus infections. Merieux Foundation, Lyon, France.
17. Chin, J., R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449-463.
18. Clements, M. L., M. K. Makhene, R. A. Karron, B. R. Murphy, M. C. Steinhoff, K. Subbarao, M. H. Wilson, Pediatric Care Center, and P. F. Wright. 1996. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. J. Infect. Dis. 173:44-51.
19. Coates, H. V., D. W. Alling, and R. M. Chanock. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am. J. Epidemiol. 83:299-313.
20. Collins, P. L., A. R. Davis, M. D. Lubeck, et al. Evaluation of the protective efficacy of recombinant vaccinia viruses and adenoviruses that express respiratory syncytial virus glycoproteins, p. 79-84. In F. Brown, R. M. Chanock, H. S. Ginsberg, and R. A. Lerner (ed.), Vaccines 90: modern approaches to vaccines including the prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
21. Collins, P. L., M. G. Hill, E. Camargo, H. Grasfeld, R. M. Chanock, and B. M. Murphy. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA 92:11563-11567.
22. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1351. In B. N. Fields (ed.), Fields virology. Raven Press, New York, N.Y.
23. Collins, P. L., R. H. Purcell, W. T. London, L. A. Lawrence, R. M. Chanock, and B. R. Murphy. 1990. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8:164-168.
24. Connors, M., P. L. Collins, C.-Y. Firestone, A. V. Sotnikov, A. Waitze, A. R. Davis, P. P. Hung, R. M. Chanock, and B. R. Murphy. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484.
25. Connors, M., P. L. Collins, C. Y. Firestone, and B. R. Murphy. 1991. Respiratory syncytial virus (RSV) F, G M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65:1634-1637.
26. + T cells. J. Virol. 66:7444-7451.
27. Corvaïa, N., P. Tournier, T. N. Nguyen, J. F. Haeuw, U. F. Power, H. Binz, and C. Andreoni. 1997. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. J. Infect. Dis. 176:560-569.
28. Crowe, J., Jr., C. Y. Firestone, S. S. Whitehead, P. L. Collins, and B. R. Murphy. 1996. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes 13:269-273.
29. Crowe, J. E., Jr, 1995. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine 13:415-421.
30. Crowe, J. E., Jr., T. B. Phuong, A. R. Davis, R. M. Chanock, and B. R. Murphy. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus (RSV cpts-248) retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790.
31. Crowe, J. E., Jr., P. T. Bui, W. T. London, A. R. Davis, P. P. Hung, R. M. Chanock, and B, R. Murphy. 1994. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691-709.
32. Crowe, J. E., Jr., P. L. Collins, R. M. Chanock, and B. R. Murphy. 1997. Vaccines against respiratory syncytial virus and parainfluenza virus type 3, p. 711-725. In M. M. Levin, G. C. Woodrow, J. B. Kaper, and G. S. Cobon. (ed.), New generation vaccines. Marcel Dekker, Inc., New York, N.Y.
33. Crowe, J. E., Jr., P. L. Collins, W. T. London, R, M. Chanock, and B. R. Murphy. 1993. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperaturesensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11:1395-1404.
34. Crowe, J. E., Jr., P. T. Bui, G. R. Siber, W. R. Elkins, R. M. Chanock, and B. R. Murphy. 1995. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13:847-855.
35. Cunningham, C. K., J. A. McMillan, and S. J. Gross. 1991. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 88:527-532.
36. Dowell, S. F., L. J. Andersen, H. E. Gary, Jr., D. D. Erdman, J. F. Plouffe, T. M. File, Jr., B. J. Marston, and R. F. Breiman. 1996. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174:456-462.
37. Falsey, A. R., C. K. Cunningham, W. H. Barker, R. W. Kouides, J. B. Yuen, M. Menegus, L. B. Weiner, C. A. Bonville, and R. F. Betts. 1995. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:389-394.
38. Falsey, A. R., J. J. Treanor, R. F. Betts, and E. E. Walsh. 1992. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40:115-119.
39. Falsey, A. R., and E. E. Walsh. 1996. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14:1214-1218.
40. Falsey, A. R., and E. E. Walsh. 1997. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15:1130-1132.
41. Falsey, A. R., and E. E. Walsh. 1998. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J. Infect. Dis. 177: 463-466.
42. Firestone, C., S. S. Whitehead, P. L. Collins, B. R. Murphy, and J. E. Crowe, Jr. 1996. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp), temperature-sensitive (ts) cpts-248/ 404 live attenuated virus vaccine candidate. Virology 225:419-422.
43. Fishaut, M., D. Tubergen, and K. McIntosh. 1980. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J. Pediatr. 96:179-186.
44. Fouillard, L., L. Mouthon, J. P. Laporte, F. Isnard, J. Stachowiak, M. Aoudjhane, J. C. Lucet, M. Wolf, F. Bricourt, L. Douay, M. Lopez, C. Marche, A. Najman, and N. C. Gorin. 1992. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant. 9:97-100.
45. Fulginiti, V. A., J. J. Eller, O. F. Sieber, J. W. Joyner, M. Minamitani, and G. Meiklejohn. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:435-448.
46. Garcia, O., M. Martin, J. Dopazo, J. Arbiza, S. Frabasile, J. Russi, M. Mortal, P. Perez-Brena, I. Martinez, B. Garcia-Barreno, et al. 1994. Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J. Virol. 68:5448-5459.
47. Glezen, W. P., A. Paredes, J. E. Allison, L. H. Taber, and A. L. Frank. 1981. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98:708-715.
48. Glezen, W. P., L. H. Taber, A. L. Frank, and J. A. Kasel. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140:543-546.
49. Gorse, G. J., E. E. Otto, D. C. Powers, G. W. Chambers, C. S. Eickhoff, and F. K. Newman. 1996. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J. Infect. Dis. 173:285-290.
50. Graham, B. S. 1995. Pathogenesis of respiratory syncytial virus vaccineaugmented pathology. Am. J. Respir. Crit. Care Med. 152:S63-S66.
51. Graham, B. S., G. S. Henderson, Y. Tang, X. Lu, K. M. Neuzil, and D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040.
52. Groothuis, J. R., K. M. Gutierrez, and B. A. Lauer. 1988. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 82:199-203.
53. Groothuis, J. R., S. J. King, D. A. Hogerman, P. R. Paradiso, and E. A. Simoes. 1998. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177:467-469.
54. Groothuis, J. R., E. A. F. Simoes, M. J. Levin, C. B. Hall, C. E. Long, W. J. Rodriguez, J. Arrobio, H. C. Meissner, D. R. Fulton, R. C. Welliver, et al. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 329:1524-1530.
55. Hall, C. B. 1994. Prospects for a respiratory syncytial virus vaccine. Science 265:1393-1394.
56. Hall, C. B., and R. G. Douglas. 1981. Modes of transmission of respiratory syncytial virus. J. Pediatr. 99:100-103.
57. Hall, C. B., J. M. Geiman, R. Biggar, D. Kotok, P. M. Hogan, and R. G. Douglas. 1976. Respiratory syncytial virus infections within families. N. Engl. J. Med. 294:414-419.
58. Hall, C. B., E. E. Walsh, C. E. Long, and K. C. Schnabel. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163:693-698.
59. Hancock, G. E., D. J. Speelman, P. J. Frenchick, M. M. Mineo-Kuhn, R. B. Baggs, and D. J. Hahn. 1995. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 13:391-400.
60. Heilman, C. A. 1990. Respiratory syncytial and parainfluenza viruses. J. Infect. Dis. 161:402-406.
61. Hemming, V. G., G. A. Prince, J. R. Groothuis, and G. R. Siber. 1995. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8:22-33.
62. Henderson, F. W., A. M. Collier, W. A. Clyde, Jr., and F. W. Denny. 1979. Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N. Engl. J. Med. 300:530-534.
63. Hendry, R. M., J. C. Burns, E. E. Walsh, B. S. Graham, P. F. Wright, V. G. Hemming, W. J. Rodriquez, H. W. Kim, G. A. Prince, K. McIntosh, R. M. Chanock, and B. R. Murphy. 1988. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J. Infect. Dis. 157:640-647.
64. Hendry, R. M., L. T. Pierik, and K. McIntosh. 1989. Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks: 1981-1987. J. Infect. Dis. 160:185-190.
65. Holberg, C. J., A. L. Wright, F. D. Martinez, C. G. Ray, L. M. Taussig, and M. D. Lebowitz. 1991. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am. J. Epidemiol. 133: 1135-1151.
66. Hsu, K.-H. L., M. D. Lubeck, A. R. Davis, R. A. Bhat, B. H. Selling, B. M. Bhat, S. Mizutani, P. P. Hung, B. R. Murphy, P. L. Collins, and R. M. Chanock. 1991. Immunogenicity and protective efficacy of adenovirus vectored respiratory syncytial virus vaccine, p. 293-297. In R. M. Chanock, F. Brown, H. S. Ginsberg, and R. A. Lerner (ed.), Vaccines 91: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
67. Hsu, K.-H. L., M. D. Lubeck, A. R. Davis, R. A. Bhat, B. H. Selling, B. M. Bhat, S. Mizutani, B. R. Murphy, P. L. Collins, and R. M. Chanock. 1992. Immunogenicity of recombinant adenovirus-respiratory syncytial virus using Ad4, Ad5, and Ad7 vectors in dogs and a chimpanzee. J. Infect. Dis. 166:769-775.
68. Johnson, P. R., Jr., R. A. Olmsted, G. A. Prince, D. W. Ailing, E. E. Walsh, and P. L. Collins. 1987, Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J. Virol. 61:3163-3166.
69. Juhasz, K., S. S. Whitehead, P. T. Bui, J. M. Biggs, C. A. Boulanger, P. L. Collins, and B. R. Murphy. 1997. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:5814-5819.
70. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421.
71. Karron, R. A., M. C. Steinhoff, E. K. Subbarao, M. H. Wilson, K. MacLeod, Pediatric Care Center, M. L. Clements, L. F. Fries, and B. R. Murphy. 1995. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr. Infect. Dis. J. 14:10-16.
72. Karron, R. A., P. F. Wright, J. E. Crowe, Jr., M. L. Clements, J. Thompson, M. Makhene, R. Casey, and B. R. Murphy. 1997. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants and children. J. Infect. Dis. 176:1428-1436.
73. Kim, H. W., J. O. Arrobio, C. D. Brandt, P. Wright, D. Hodes, R. M. Chanock, and R. H. Parrott. 1973. Safety and antigenicity of temperature-sensitive (ts) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 52:56-63.
74. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
75. Kim, H. W., S. L. Leikin, J. Arrobio, C. D. Brandt, R. M. Chanock, and R. H. Parrott. 1976. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr. Res. 10:75-78.
76. Lamprecht, C. L., H. E. Krause, and M. A. Mufson. 1976. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J. Infect. Dis. 134:211-217.
77. MacDonald, N. E., C. B. Hall, S. C. Suffin, C. Alexson, P. J. Harris, and J. A. Manning. 1982. Respiratory syncytial viral infection in infants with congenital heart disease. N. Engl. J. Med. 307:397-100.
78. Martin-Gallard, A., E. Fleischer, S. A. Doyle, R. Arumugham, P. L. Collins, S. W. Hildreth, and P. R. Paradiso. 1993. Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. Gen. Virol. 74:453-158.
79. McConnochie, K. M., C. B. Hall, E. E. Walsh, and K. J. Roghmann. 1990. Variation in severity of respiratory syncytial virus infections with subtype. J. Pediatr. 117:52-62.
80. McIntosh, K., A. M. Arbeter, M. K. Stahl, I. A. Orr, D. S. Hodes, and E. C. Ellis. 1974. Attenuated respiratory syncytial virus vaccines in asthmatic children. Pediatr. Res. 8:689-696,
81. McIntosh, K., H. B. Masters, I. Orr, R. K. Chao, and R. M. Barkin. 1978. The immunologic response to infection with respiratory syncytial virus in infants. J. Infect. Dis. 138:24-32.
82. McKay, E., P. Higgins, D. Tyrrell, and C. Pringle. 1988. Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J. Med. Virol. 25:411-121.
83. Mills, J., J. E. Van Kirk, P. F. Wright, and R. M. Chanock. 1971. Experimental respiratory syncytial virus infection of adults. J. Immunol. 107:123-130.
84. Mlinaric-Galinovic, G., A. R. Falsey, and E. E. Walsh. 1996. Respiratory syncytial virus infection in the elderly. Eur. J. Clin. Microbiol. Infect. Dis. 15:777-781.
85. Mufson, M. A., R. B. Belshe, C. Orvell, and E. Norrby. 1988. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. J. Infect. Dis. 157:143-148.
86. Mufson, M. A., M. J. Levin, R. E. Wash, H. E. Mocega-Gonzales, and H. E. Krause. 1973. Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am. J. Epidemiol. 98:88-95.
87. Murphy, B. R., D. W. Ailing, M. H. Snyder, E. E. Walsh, G. A. Prince, R. M. Chanock, V. G. Hemming, W. J. Rodriguez, H. W. Kim, B. S. Graham, and P. F. Wright. 1986. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J. Clin. Microbiol. 24:894-898.
88. Murphy, B. R., S. L. Hall, A. B. Kulkarni, J. E. Crowe, P. L. Collins, M. Connors, R. A. Karron, and R. M. Chanock. 1994. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:13-36.
89. Murphy, B. R., G. A. Prince, E. E. Walsh, H. W. Kim, R. H. Parrott, V. G. Hemming, W. J. Rodriguez, and R. M. Chanock. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24:197-202.
90. Murphy, B, R., A. V. Sotnikov, L. A. Lawrence, S. M. Banks, and G. A. Prince. 1990. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8:497-502.
91. Murphy, B. R., A. V. Sotnikov, P. R. Paradiso, S. W. Hildreth, A. B. Jenson, R. B. Baggs, L. Lawrence, J. J. Zubak, R. M. Chanock, J. A. Beeler, et al. 1989. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7:533-540.
92. Neuzil, K. M., J. E. Johnson, Y. Tang, J. Prieel, M. Slaoui, N. Gar, and B. S. Graham. 1997. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 15:525-532.
93. Oien, N. L., R. J. Brideau, E. E. Walsh, and M. W. Wathen. 1994. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 12:731-735.
94. Paradiso, P. R., S. W. Hildreth, D. A. Hogerman, D. J. Speelman, E. B. Lewin, J. Oren, and D. H. Smith. 1994. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr. Infect. Dis. J. 13:792-798.
95. Paradiso, P. R. Personal communication.
96. Piazza, R. M., S. A. Johnson, M. E. R. Darnell, D. D. Porter, V. G. Hemming, and G. A. Prince. 1993. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection. J. Virol. 67:1503-1510.
97. Piedra, P. A., S. Grace, A. Jewell, S. Spinelli, D. Bunting, D. A. Hogerman, F. Malinoski, and P. W. Hiatt. 1996. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J. 15:23-31.
98. Prevent Study Group. 1997. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99:93-99.
99. Prince, G. A., R. L. Horswood, E. Camargo, D. Koenig, and R. M. Chanock. 1983. Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect. Immun. 42:81-87.
100. Prince, G. A., R. L. Horswood, and R. M. Chanock. 1985. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 55:517-520.
101. Prince, G. A., M. Redington, R. M. Piazza, and V. G. Hemming. 1991. Bovine respiratory syncytial virus provides protection against human respiratory syncytial virus infection in cotton rats and primates, p. 133-136. In B. Meignier, B. Murphy, and P. Ogra (ed.), Animal models of respiratory syncytial virus infections. Merieux Foundation, Lyon, France.
102. Pringle, C. R., A. H. Filipiuk, B. S. Robinson, P. J. Watt, P. Higgins, and D. A. J. Tyrrell. 1993. Immunogenicity and pathogenicity of a triple temrature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11:473-478.
103. Randolph, V. B., M. Kandis, P. Stemler-Higgins, M. S. Kennelly, Y. M. McMullen, D. J. Speelman, and C. Weeks-Levy. 1994. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation. Virus Res. 33:241-259.
104. Randolph, V. B. Personal communication.
105. Richardson, L. S., R. H. Yolken, R. B. Belshe, et al. 1978. Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection. Infect. Immun. 23:660-664.
106. Rodriguez, W. J., W. C. Gruber, R. C. Welliver, J. R. Groothuis, E. A. Simoes, H. C. Meissner, V. G. Hemming, C. B. Hall, M. L. Lepow, A. J. Rosas, C. Robertson, and A. A. Kramer. 1997. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 99:454-461.
107. Spence, L., and N. Barratt. 1968. Respiratory syncytial virus associated with acute respiratory infections in Trinidadian patients. Am. J. Epidemiol. 88:257-266.
108. Storch, G. A., L. J. Anderson, C. S. Park, C. Tsou, and D. E. Dohner. 1991. Antigenic and genomic diversity within group A respiratory syncytial virus. J. Infect. Dis. 163:858-861.
109. Sollender, W. M., K. Anderson, and G. W. Wertz. 1990. The respiratory syncytial virus subgroup B attachment glycoprotein: analysis of sequence, expression from a recombinant vector, and evaluation as an immunogen against homologous and heterologous subgroup virus challenge. Virology 178:195-203.
110. Sullender, W. M., and W. J. Britt. 1996. Antigenic and immunogenic analysis of group A and group B respiratory syncytial virus G proteins expressed from recombinant baculoviruses. J. Gen. Virol. 77:641-648.
111. Tang, Y. W., and G. S. Graham. 1995. Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. J. Infect. Dis. 172:734-738.
112. Taylor, C. E., S. Morrow, M. Scott, B. Young, and G. L. Toms. 1989. Comparative virulence of respiratory syncytial virus subgroups A and B. Lancet i:777-778.
113. Tolley, K. P., A. C. Marriott, A. Simpson, D. J. Plows, D. A. Matthews, S. J. Longhurst, J. E. Evans, J. R. Johnson, P. A. Cane, V. B. Randolph, A. J. Easton, and C. R. Pringle. 1996. Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus. Vaccine 14:1637-1646.
114. Treanor, J. J., H. R. Mattison, G. Dumyati, A. Yinnon, S. Erb, D. O'Brien, R. Dolin, and R. F. Betts. 1992. Protective efficacy of combined live intrasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 117:625-633.
115. Tristram, D. A., R. C. Welliver, C. K. Mohar, D. A. Hogerman, S. W. Hildreth, and P. Paradiso. 1993. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167:191-195.
116. Trudel, M., F. Nadon, C. Seguin, and H. Binz. 1991. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology 185:749-757.
117. Trudel, M., E. J. Stott, G. Taylor, D. Oth, G. Mercier, F. Nadon, C. Seguin, C. Simard, and M. Lacroix. 1991. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection. Arch. Virol. 117:59-71.
118. Walsh, E. E. 1994. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J. Infect. Dis. 170:345-350.
119. Walsh, E. E., C. B. Hall, M. Briselli, M. W. Brandriss, and J. J. Schlesinger. 1987. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J. Infect. Dis. 155:1198-1204.
120. Walsh, E. E., K. M. McConnochie, C. E. Long, and C. B. Hall. 1997. Severity of respiratory syncytial virus infection is related to virus strain. J. Infect. Dis. 175:814-820.
121. Walsh, E. E., J. J. Schlesinger, and M. W. Brandriss. 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43:756-758.
122. Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson. 1996. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:2852-2860.
123. Wathen, M. W., R. J. Brideau, D. R. Thomsen, and B. R. Murphy. 1989. Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector. J. Gen. Virol. 70:2625-2635.
124. Wathen, M. W., T. J. Kakuk, R. J. Brideau, E. C. Hausknecht, S. L. Cole, and R. M. Zaya. 1991. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J. Infect. Dis. 163:477-482.
125. Watt, P. J., M. Zardis, and P. R. Lambden. 1986. Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants. Clin. Exp. Immunol. 64:503-509.
126. Wright, P. F., T. Shinozaki, W. Fleet, S. H. Sell, J. Thompson, and D. T. Karzon. 1976. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J. Pediatr. 88:931-936.